FY2017 EPS Estimates for Teladoc Inc Raised by Oppenheimer (NYSE:TDOC)

Teladoc Inc (NYSE:TDOC) – Investment analysts at Oppenheimer lifted their FY2017 earnings estimates for shares of Teladoc in a research note issued on Tuesday, according to Zacks Investment Research. Oppenheimer analyst M. Naidu now forecasts that the health services provider will earn ($1.54) per share for the year, up from their previous estimate of ($1.56). Oppenheimer currently has a “Outperform” rating and a $45.00 target price on the stock. Oppenheimer also issued estimates for Teladoc’s Q4 2017 earnings at ($0.40) EPS, Q2 2018 earnings at ($0.34) EPS, Q3 2018 earnings at ($0.25) EPS, Q4 2018 earnings at ($0.17) EPS, FY2018 earnings at ($1.12) EPS, Q1 2019 earnings at ($0.24) EPS, Q2 2019 earnings at ($0.22) EPS, Q3 2019 earnings at ($0.19) EPS, Q4 2019 earnings at ($0.10) EPS and FY2019 earnings at ($0.75) EPS.

A number of other research analysts also recently weighed in on the company. SunTrust Banks restated a “buy” rating and issued a $40.00 price target on shares of Teladoc in a research note on Friday, November 3rd. Deutsche Bank initiated coverage on Teladoc in a research report on Friday, December 8th. They issued a “buy” rating and a $39.00 price objective for the company. Canaccord Genuity set a $42.00 price objective on Teladoc and gave the company a “buy” rating in a research report on Friday, November 17th. BidaskClub cut Teladoc from a “hold” rating to a “sell” rating in a research report on Wednesday, November 15th. Finally, Zacks Investment Research cut Teladoc from a “buy” rating to a “hold” rating in a research report on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $39.43.

Teladoc (NYSE TDOC) traded down $1.75 during mid-day trading on Thursday, reaching $35.30. The company’s stock had a trading volume of 1,346,196 shares, compared to its average volume of 1,284,640. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.08 and a current ratio of 5.08. The company has a market capitalization of $2,013.83, a P/E ratio of -24.51 and a beta of 0.49. Teladoc has a 12-month low of $19.60 and a 12-month high of $38.40.

In related news, CEO Jason N. Gorevic sold 100,000 shares of Teladoc stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $32.99, for a total transaction of $3,299,000.00. Following the completion of the sale, the chief executive officer now directly owns 718,261 shares of the company’s stock, valued at approximately $23,695,430.39. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Mark Hirschhorn sold 30,000 shares of Teladoc stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $32.99, for a total value of $989,700.00. Following the sale, the chief financial officer now directly owns 5,203 shares of the company’s stock, valued at $171,646.97. The disclosure for this sale can be found here. Company insiders own 4.47% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in TDOC. SG Americas Securities LLC acquired a new stake in Teladoc during the 4th quarter worth approximately $101,000. ETF Managers Group LLC acquired a new stake in Teladoc during the 2nd quarter worth approximately $104,000. Pacad Investment Ltd. acquired a new stake in Teladoc during the 2nd quarter worth approximately $135,000. Fred Alger Management Inc. bought a new position in Teladoc during the 2nd quarter worth $139,000. Finally, Ameritas Investment Partners Inc. increased its stake in Teladoc by 134.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock worth $164,000 after acquiring an additional 2,707 shares during the period.

TRADEMARK VIOLATION NOTICE: “FY2017 EPS Estimates for Teladoc Inc Raised by Oppenheimer (NYSE:TDOC)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/04/brokers-issue-forecasts-for-teladoc-incs-fy2017-earnings-tdoc.html.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Get a free copy of the Zacks research report on Teladoc (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply